Etofibrate: Difference between revisions
No edit summary |
No edit summary |
||
Line 24: | Line 24: | ||
| routes_of_administration = | | routes_of_administration = | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
Line 33: | Line 32: | ||
==References== | ==References== | ||
{{ | {{reflist|2}} | ||
{{Lipid modifying agents}} | {{Lipid modifying agents}} | ||
[[Category:Drug]] | |||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Fibrates]] | [[Category:Fibrates]] | ||
Revision as of 16:49, 27 July 2014
{{drugbox | IUPAC_name = 2-{[2-(4-chlorophenoxy)-2-methylpropanoyl]oxy}ethyl nicotinate | image = Etofibrate svg.png | CAS_number = 31637-97-5 | ATC_prefix = C10 | ATC_suffix = AB09 | PubChem = 65777 | DrugBank = | C=18|H=18|Cl=1|N=1|O=5 | molecular_weight = 363.792 g/mol | bioavailability = | protein_bound = | metabolism = Hydrolyzed to clofibric acid and niacin | elimination_half-life = | excretion = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = }}
WikiDoc Resources for Etofibrate |
Articles |
---|
Most recent articles on Etofibrate |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Etofibrate at Clinical Trials.gov Clinical Trials on Etofibrate at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Etofibrate
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Etofibrate Discussion groups on Etofibrate Patient Handouts on Etofibrate Directions to Hospitals Treating Etofibrate Risk calculators and risk factors for Etofibrate
|
Healthcare Provider Resources |
Causes & Risk Factors for Etofibrate |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Etofibrate is a fibrate. It is a combination of clofibrate and niacin, linked together by an ester bond. In the body, clofibrate and niacin separate and are released gradually, in a manner similar to controlled-release formulations.[1]
References
- ↑ Sposito AC, Mansur AP, Maranhão RC, Rodrigues-Sobrinho CR, Coelho OR, Ramires JA (2001). "Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects". Braz J Med Biol Res. 34 (2): 177–82. PMID 11175492. Free full text